BioVersys and Shionogi Enter Into Global Research Collaboration For Broad-Spectrum Non-Tuberculous Mycobacteria (NTM) Clinical Candidate
Ad hoc announcement pursuant to Art. 53 LR BASEL, Switzerland, July 02, 2025 (GLOBE NEWSWIRE) — The Global Research Collaboration is a research and exclusive license option agreement with Shionogi to jointly develop novel ansamycin leads from BioVersys' BV500 program into clinical candidates Shionogi gets access to BioVersys' proprietary ansamycin platform and the BV500 program […]